So I was thinking about yesterday, and what it's safe to talk about with respect to work. I'm gonna take *some* risk here, but ... essentially, I'm not a ROM hacker or an emudev. Those are hobbies. My specific talent is reverse engineering, which is a much more broad category.

6th SUNDAY SPECIAL #ShoutOut

Hard Core Right Wingers

Step 1-Retweet ALL Lists

Step 2-Follow ALL 289 Handles in ALL 17 Lists

Step 3-Honestly FOLLOW BACK the ONEs who follow u

Earlier Lists welcome for Multiplying

सब जुड़ जाओ, एक हो जाओ

RW को फ़ौलाद💪बना दो

#HinduEcosystem

List 1

@FltLtAnoopVerma
@mickeyanoop
@Bharatiyasatyam
@ModIfiedAksHIT
@AshishMakhijani
@AbePappi
@Neh_hope_faith
@VenkateshBung
@IndianSarthak01
@iMuditJain
@ShravanBJYM
@DrxPragya
@isinghDeepanshu
@suyashdeep
@SuyashJ09
@TusharKant_Naik
@arunkdimpu
@Coachketang

#HinduEcosystem

List 2

@thisissAnjaliG
@Naiktanmay111
@NikhilChelsea12
@IvaSaina
@neil_sane
@aarti162004
@AppamWidUndhiyu
@The_NitinD
@Nitin_vn46
@NikhilBhamre8
@C_JackMH26
@SimzAU
@Impregnable007
@Manika_0315
@BhatiaCrish
@LibtardsKaDoc
@Horse_stable13
@oldschoolmonk1
@Anu_2208
#HinduEcosystem

List 3

@Aartitva
@TraderChirag
@ibonthewayindia
@RubishRaja
@NidarAryan
@doubtfulLucifer
@pandey_kill_bil
@PrathamShashank
@SanataniMarwadi
@DubeyYash1911
@bayonetwarrior
@satyamev21
@parasadukia
@Sanghi_wrath
@hritwik_paul
@just_bhakt
@ss_aarthi
@JRamlingam

#HinduEcosystem

List 4

@UshaNirmala
@Ajusan123
@Nayak1812
@Ayush_Shah_25
@shakti050
@kunaljain_19
@HashtagAviral
@abhi_rocks1004
@sanghini_
@GouriBhide
@KhamanDhokIa
@Shreyas54125712
@Shreya1176
@shubham_ag7
@proudsanghii
@sanghialien
@_Sanghi_Saffron
@saffronpride_
@BHARTIYFOJI
#HinduEcosystem

#SuvenLife – Niche R&D play..very high risk and very high reward…key is right allocation…

Jazz Pharma was quoting around $0.5 in 2009, today its $150 and Mcap of $8.5 Bn on Nasdaq..almost 300x in 11 years. 80% of its total sales ($2.1 Bn) come from single drug Xyrem.

Axovant Lifescience, bought Alzheimer molecule from GSK, repackaged it and done phase-3 trials. Before starting the trials, the valuation was $2 Bn, just before announcing the data, it rose to $3 Bn. One of the leading broker put the target of $12 Bn if the trials succeeded..

but it failed in phase-3 trials. Current Mcap is $120 Mn…

This is R&D for New Chemical Entity (NCE)…very high risk and very high reward…

Brain-related illnesses, also known as CNS diseases, afflict more than 2 billion people worldwide. Diseases of the brain and mind range

from Alzheimer’s, dementia, epilepsy, migraine, multiple sclerosis, neuro infections, Parkinson’s, psychosis, schizophrenia and stroke to brain injuries and various mental disorders. The global market or CNS therapeutics is projected to reach $137.7 billion by 2025.

#SuvenLife has 1 lead molecule SUVN-G3031 in phase-2 trials which is similar to Xyrem but superior features, 3 molecules completed phase-1 trials and starting phase-2 trials and 11 molecules in pre-clinical trials. All are related to CNS which is growing and uncluttered market

We are belatedly entering the hearing.

Ian Wise is setting out arguments.

#StopStonewall

Ian Wise:

Transgenderism is very controversial territory. ‘Perceived by the victim’ very controversial.

References the Miller case. Complaint could be made by third party.

#StopStonewall

Ian Wise:

A comment that is ‘perceived’ to be transphobic.

In the Miller case this led to police action which was found to be unlawful.

#StopStonewall

Ian Wise:

My client is concerned that a boy may enter the girls toilets.

On page 336, Activity 1c we see the toilet activity.

My client has a genuine concern.

She has sufficient interest in the application.

#StopStonewall